Portfolio Company · Operating Co.

Cinclus Pharma

Pharmaceuticals

backed byTrill Impact

CurrentPharmaceuticals

Cinclus Pharma

a portfolio company of

Trill Impact

Status on record: Current

PE Firm Index

Who owns Cinclus Pharma?

Cinclus Pharma is listed as a current portfolio company of Trill Impact on Trill Impact's own portfolio page.

Company Snapshot

Cinclus Pharma is a Pharmaceuticals company. Its owner on record, Trill Impact, is a buyout firm. Trill Impact lists 20 companies in the index, 5 of them in Pharmaceuticals.

SectorPharmaceuticals

Parent PE firmTrill Impact

Ownership statusCurrent

WebsiteNot on record

About the owner

Trill Impact

Strategy: Buyout, Ventures, Microfinance, Private debt lending
Sectors: Green Tech, Life Science, Space tech
Companies in the index: 20

Trill Impact is a private markets firm that invests in companies and debt aiming to deliver financial returns through investments that matter for current and future generations.

Read the Trill Impact profile

Questions about Cinclus Pharma

Who owns Cinclus Pharma?

Cinclus Pharma is listed as a current portfolio company of Trill Impact on Trill Impact's own portfolio page.

What sector is Cinclus Pharma in?

Cinclus Pharma is in Pharmaceuticals. Classified from the owner's portfolio label.

What else does Trill Impact own in Pharmaceuticals?

Trill Impact lists 4 other Pharmaceuticals companies in the index, including May Health, Mesalvo, MinervaX and TT Medic.

Sources

Trill Impact
https://www.trillimpact.com/portfolio-companies

This profile is based on publicly available information and may be incomplete or outdated. PE Firm Index is not affiliated with Cinclus Pharma and does not provide investment advice.

Other portfolio companies of Trill Impact

6 of 19 shown

Allurity

Cybersecurity Services

Infrastructure Services

See the full Trill Impact portfolio.

Other Pharmaceuticals companies held by Trill Impact

May Health Mesalvo MinervaX TT Medic

Other Pharmaceuticals portfolio companies

via Wavemaker 360 Health

3P Biopharmaceuticals

via Marlin Equity Partners

Browse PE-backed companies.

Is this your company?

Claiming is free and reviewed by hand. Correct facts and add your team.

Claim this profile Suggest a correction

Ownership

Parent PE firm

Trill Impact

Status: Current

For PE-backed companies

DevriX

DevriX runs the websites, integrations and data that bring in revenue, as one accountable engineering and operations team, through acquisitions and exit.

Where DevriX helps

Value creation through the holdRevenue, data, web and AI run as one operating cadence, tied to EBITDA.Add-ons and carve-outsConsolidate or separate platforms and unify reporting after a deal.Exit readinessFind the technology and data issues a buyer's diligence would raise, before it does.

Send DevriX a short brief

A short form on devrix.com. No call to book.

Disclosure: PE Firm Index is maintained by Mario Peshev, who founded and runs DevriX. DevriX listing

Weekly PE M&A and market research, by email

The Growth Shuttle Insider is Mario Peshev's weekly newsletter for PE owners and operators. Each issue carries the week's private equity deals from this index, market data and research, and an essay from Mario.

Free. One email a week. Unsubscribe from any issue. Your address goes to beehiiv, the service that sends the Insider.

Research

The 2027 Digital Value Creation Baseline

1,407 PE-backed companies from 179 sponsors, measured from public sources in October 2026. 15% of service and product companies have the full path from search to CRM.

Read the research

Research by Growth Shuttle and DevriX.